focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Regulatory News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Offer Update - Court sanction of the Scheme

21 Dec 2011 10:49

RNS Number : 4085U
Investec PLC
21 December 2011
 



Investec Limited

Incorporated in the Republic of South Africa

Registration number 1925/002833/06

JSE share code: INL

ISIN: ZAE000081949

Investec plc

Incorporated in England and Wales

Registration number 3633621

JSE share code: INP

ISIN: GB00B17BBQ50

 

(jointly "Investec")

 

As part of the dual listed company structure, Investec plc and Investec Limited notify both the London Stock Exchange and the JSE Limited of matters which are required to be disclosed under the Disclosure, Transparency and Listing Rules of the United Kingdom Listing Authority (the "UKLA") and/or the JSE Listing Requirements.

 

Accordingly, we advise of the following:

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

21 December 2011

The Evolution Group Plc ("Evolution" or the "Company")

Offer Update - Court sanction of Scheme of arrangement

On 9 September 2011, the Evolution Directors and the Board of Directors of Investec plc ("Investec") announced that they had reached agreement on the terms of a recommended share offer ("the Offer"), to be implemented by way of a Court sanctioned scheme of arrangement under Part 26 of the Companies Act 2006 (the "Scheme"), under which it was proposed that Investec would acquire the entire issued ordinary share capital of Evolution. A scheme document to shareholders of Evolution (the "Scheme Document"), containing further information on the Scheme, was published on 3 October 2011. The Scheme and its implementation was approved by the shareholders of Evolution on 27 October 2011.

Investec and Evolution are pleased to announce that the Court has today made an order to sanction the Scheme to give effect to the Offer. The Scheme will become effective on delivery of the Court order to the Registrar of Companies, which is expected to take place on 22 December 2011, whereupon the entire issued ordinary share capital of Evolution will be owned by Investec.

A request has been made to the UK Listing Authority and the London Stock Exchange for a suspension of the listing of, and dealings in, Evolution Shares with effect from 4.30 p.m. today, 21 December 2011. Evolution Shareholders on the register at the Scheme Record Time, being 6.00 p.m. on 21 December 2011, will receive 0.23124 New Investec Shares for each Scheme Share held.

Admission of the New Investec Shares to listing on the Official List of the UK Listing Authority (the "Official List") and to trading on the London Stock Exchange's main market for listed securities (the "Main Market") and the Johannesburg Stock Exchange is expected to occur with effect from 8.00 a.m. (UK time) tomorrow, 22 December 2011.

Settlement of the New Investec Shares held through CREST is expected to take place by 8.00 a.m. (UK time) tomorrow, 22 December 2011. Share certificates in relation to the New Investec Shares to be held in certificated form will be despatched no later than 5 January 2012.

The admission to trading of Evolution Shares on the Main Market and the listing of Evolution Shares on the Official List is expected to be cancelled at Evolution' request with effect from 8.00 a.m.(UK time) tomorrow, 22 December 2011.

Defined terms used but not defined in this announcement have the meanings set out in the Scheme Document.

Enquiries:

Evolution

Alex Snow

 

+44 (20) 7071 4300

 

Investec

Ursula Nobrega

Stephen Koseff

Bernard Kantor

 

+44 (20) 7597 5546

 

Credit Suisse (Financial Adviser to Evolution)

George Maddison

Joe Hannon

 

+44 (20) 7888 8888

 

Investec Investment Banking (Financial Adviser and Joint Corporate Broker to Investec)

David Currie

Christopher Baird

James Ireland

 

+44 (20) 7597 5970

 

Pelham Bell Pottinger (Financial PR to Evolution)

Victoria Geoghegan

 

+44 (20) 7861 3925

 

Citigate Dewe Rogerson (Financial PR to Investec)

Tom Baldock

Justin Griffiths

+44 (20) 7638 9571

 

Credit Suisse, which is authorised and regulated in the UK by the Financial Services Authority, is acting exclusively for Evolution and no one else in connection with the Offer and this announcement and will not be responsible to anyone other than Evolution for providing the protections afforded to clients of Credit Suisse or for providing advice in connection with the Offer or any matter referred to herein.

Investec Investment Banking, a division of Investec Bank plc, which is authorised and regulated in the UK by the Financial Services Authority, is acting for Investec and no one else in connection with the Offer and this announcement and will not be responsible to anyone other than Investec for providing the protections afforded to clients of Investec Investment Banking or for providing advice in connection with the Offer or any matter referred to herein.

This announcement is for information purposes only and does not constitute an offer to sell or an invitation to purchase any securities or the solicitation of an offer to buy any securities, pursuant to the Offer or otherwise. This announcement has been prepared for the purpose of complying with English law and the City Code and the information disclosed may not be the same as that which would have been disclosed if this announcement had been prepared in accordance with the laws of jurisdictions outside the United Kingdom.

The release, publication or distribution of this announcement in certain jurisdictions may be restricted by law. Persons who are not resident in the United Kingdom or who are subject to other jurisdictions should inform themselves of, and observe, any applicable requirements.

A copy of this announcement will be made available, free of charge, at www.evgplc.com and www.investec.com by no later than 12 noon (London time) on 22 December 2011.

You may request a hard copy of this announcement, free of charge, by contacting the Company Secretary of Evolution on +44 (20) 7071 4300. You may also request that all future documents, announcements and information to be sent to you in relation to the Offer should be in hard copy form.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
OUPBFLFLFLFZFBD
Date   Source Headline
25th Apr 20243:46 pmRNSChange of Name
22nd Apr 202410:11 amRNSHolding(s) in Company
11th Apr 20243:04 pmRNSHolding(s) in Company
9th Apr 20247:00 amRNSHolding(s) in Company
8th Apr 20244:03 pmRNSHolding(s) in Company
5th Apr 20243:39 pmRNSDirector/PDMR Shareholding
5th Apr 20242:40 pmRNSHolding(s) in Company
4th Apr 20241:59 pmRNSResult of General Meeting
4th Apr 20247:00 amRNSResult of Retail Offer
19th Mar 20245:03 pmRNSRetail Offer
19th Mar 20245:00 pmRNSAcquisition, Fundraising and Change of Name
27th Feb 20247:00 amRNSSFX-01 positive update in bowel cancer models
19th Feb 202411:22 amRNSPositive update on SFX-01 in vitro GBM studies
9th Feb 202411:01 amRNSNotice of Dispute lodged with Stalicla SA
16th Jan 20243:07 pmRNSSeries B Fund Raise by partner, Stalicla SA
29th Dec 202311:29 amRNSHolding(s) in Company
22nd Dec 20237:00 amRNSDirectorate Changes
13th Nov 20237:00 amRNSUpcoming conferences
31st Oct 20237:00 amRNSHalf-year Report
26th Oct 20237:00 amRNSErasmus Medical Center begins glioblastoma studies
19th Oct 20232:26 pmRNSAuthored Article Publication
5th Sep 20237:00 amRNSDirectorate Changes
15th Aug 20237:00 amRNSFinal Report from Phase 1b PK/PD study
3rd Aug 202312:38 pmRNSRule 17 Disclosure
2nd Aug 20237:00 amRNSReturn of rights to Sulforadex from Juvenescence
21st Jul 202312:02 pmRNSResult of AGM
27th Jun 20237:00 amRNSSFX-01 radiosensitisation effect confirmed in-vivo
20th Jun 20231:59 pmRNSNotice of AGM & Posting of Annual Report
19th Jun 20237:00 amRNSGrant Success for Glioblastoma studies
7th Jun 20237:00 amRNSFinal Results
26th May 202311:00 amRNSNotice of Results
22nd Mar 20237:00 amRNSPreliminary results from Phase 1b study
16th Mar 20232:00 pmRNSPrice Monitoring Extension
16th Mar 202311:05 amRNSSecond Price Monitoring Extn
16th Mar 202311:00 amRNSPrice Monitoring Extension
16th Mar 20237:00 amRNSFurther evidence of radiosensitisation by SFX-01
13th Mar 20237:00 amRNSNo exposure to Silicon Valley Bank
25th Jan 20237:00 amRNSClinical trial update
14th Dec 20225:08 pmRNSGrant of Options - Director/PDMR Shareholding
12th Dec 202211:54 amEQSEvgen Pharma 'cash runway in pretty good shape'
8th Dec 20227:00 amRNSHalf-year Report
2nd Dec 20227:00 amRNSNotice of Half Year Results
30th Nov 20222:06 pmRNSSecond Price Monitoring Extn
30th Nov 20222:00 pmRNSPrice Monitoring Extension
16th Nov 20227:00 amRNSStudy started of new SFX-01 tablet formulation
21st Oct 202211:05 amRNSSecond Price Monitoring Extn
21st Oct 202211:00 amRNSPrice Monitoring Extension
12th Oct 20224:41 pmRNSSecond Price Monitoring Extn
12th Oct 20224:35 pmRNSPrice Monitoring Extension
12th Oct 20227:00 amRNSClinical trial update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.